{
  "completed": true,
  "local_date": "2026-10-09",
  "checked_utc": "2026-10-10T02:58:18.768457+00:00",
  "provider": "Consensus",
  "provider_mode": "Consensus browser Pro plus connector search/fetch, reconciled with original primary PubMed abstracts",
  "queries": [
    "alpha synuclein Parkinson disease causal necessity sufficiency immunotherapy randomized trial prasinezumab cinpanemab SNCA human genetic mutations",
    "Through 3 October 2026, critically evaluate whether misfolded alpha-synuclein directly causes dopamine-neuron loss in typical sporadic Parkinson disease. Distinguish familial SNCA genetic causality, animal/model neurotoxicity and seeding, selective toxic-species removal, human causal necessity, and target-engaged clinical outcomes. Compare primary PASADENA, SPARK and PADOVA trials and exploratory follow-ups without counting the same trial twice; identify strongest supportive and contradictory primary evidence with PMID/DOI."
  ],
  "raw_paths": [
    "consensus-search.json",
    "11f55a96e0375e878f4a8a3d81c1d753.json",
    "b9ecf5e8143857e1b22371bd3a0b9e40.json",
    "d53bdce6518e5c39a09f52220c475381.json",
    "browser-thread.json",
    "consensus-browser-response.md"
  ],
  "primary_comparisons": [
    {
      "pmid": "35921451",
      "doi": "10.1056/NEJMoa2202867",
      "title": "Trial of Prasinezumab in Early-Stage Parkinson's Disease.",
      "access_depth": "abstract_metadata",
      "original_artifact": "primary.xml.records.json",
      "claim_checked": "PASADENA primary global progression and imaging outcomes did not improve meaningfully versus placebo.",
      "reconciliation": "Matches existing E51/[51]. Antibody exposure is not selective intracellular toxic-conformer depletion; a negative trial does not falsify every alpha-synuclein mechanism.",
      "verification": "verified",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35921451/",
      "status_notices": [
        {
          "type": "CommentIn",
          "pmid": "35921458",
          "note": ""
        },
        {
          "type": "CommentIn",
          "pmid": "36151474",
          "note": ""
        },
        {
          "type": "CommentIn",
          "pmid": "36404558",
          "note": ""
        },
        {
          "type": "CommentIn",
          "pmid": "36519627",
          "note": ""
        }
      ]
    },
    {
      "pmid": "35921450",
      "doi": "10.1056/NEJMoa2203395",
      "title": "Trial of Cinpanemab in Early Parkinson's Disease.",
      "access_depth": "abstract_metadata",
      "original_artifact": "primary.xml.records.json",
      "claim_checked": "SPARK found no clinical or DaT-SPECT benefit and stopped for lack of efficacy.",
      "reconciliation": "Matches E55/[55]. Distinct trial from PASADENA; no positive clinical causal threshold established.",
      "verification": "verified",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35921450/",
      "status_notices": []
    },
    {
      "pmid": "39379705",
      "doi": "10.1038/s41591-024-03270-6",
      "title": "Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.",
      "access_depth": "abstract_metadata",
      "original_artifact": "primary.xml.records.json",
      "claim_checked": "The PASADENA extension reported slower motor progression against an external observational comparator.",
      "reconciliation": "Matches E53/[53]. Exploratory open-label comparison, not concurrent-placebo replication. Same NCT03100149 family as E51; no additional independent randomized causal line.",
      "verification": "verified",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39379705/",
      "status_notices": []
    }
  ],
  "grade_changed": false,
  "prior_level": "Γ",
  "new_level": "Γ",
  "prior_confidence": "Moderate",
  "new_confidence": "Moderate",
  "review_type": "Retrospective consistency check with prior score visible; not independent blinded adjudication",
  "conclusion": "Hold the original SC1 Ζ / SC2 Γ / SC3 Γ / SC4 Γ and scope-matched overall Γ. These three rediscovered primary reports were already included and their Results agree with the original appraisals. No added source or independent causal line is credited.",
  "addendum_path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-addendum.md",
  "thread_url": "https://consensus.app/search/alpha-synuclein-parkinson-causality/HQ86Wa25Rl6VsUDvHSlliw/",
  "additional_original_source_receipts": [],
  "primary_comparison_count": 3,
  "status": "completed_retrospective_original_source_reconciliation",
  "score_before": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "The mechanistic capability is supported across approaches and clinical primary results are verified against retrieved primary abstracts. Toxic-species assignment, physiology/exposure dependence, reused cohorts, partial full-text access and unresolved corrected-appendix details limit confidence in the full human scope; this is an evidence/access band, not a probability that α-synuclein is harmless.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "Scope-matched preregistration yields SC4 Γ for the full human direct-toxicity/PD-loss claim; SC1 Ζ for familial SNCA biology is preserved separately. The examined causal work establishes more than association, but does not yet isolate the specified endogenous human toxic mediator and survival dependency. Null trials are not treated as complete mechanistic refutations."
  },
  "score_after": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "The mechanistic capability is supported across approaches and clinical primary results are verified against retrieved primary abstracts. Toxic-species assignment, physiology/exposure dependence, reused cohorts, partial full-text access and unresolved corrected-appendix details limit confidence in the full human scope; this is an evidence/access band, not a probability that α-synuclein is harmless.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "Scope-matched preregistration yields SC4 Γ for the full human direct-toxicity/PD-loss claim; SC1 Ζ for familial SNCA biology is preserved separately. The examined causal work establishes more than association, but does not yet isolate the specified endogenous human toxic mediator and survival dependency. Null trials are not treated as complete mechanistic refutations."
  },
  "raw_receipts": [
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-search.json",
      "sha256": "f2a3bf445075eed53e5165157202f45e4e5bdc3185da0fb5f5029eb6cbf8039b"
    },
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\11f55a96e0375e878f4a8a3d81c1d753.json",
      "sha256": "e1bb5e2223c084e0f7d41eebd65f500f3f52ea9155687000ba186dbf93099e62"
    },
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\b9ecf5e8143857e1b22371bd3a0b9e40.json",
      "sha256": "086df925bcb53f8cb629fa44a536ccd6cf72713f7b409e4445c1bd538f922718"
    },
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\d53bdce6518e5c39a09f52220c475381.json",
      "sha256": "0657a80fd8f8ca746d5d94623816231b2d2c71839d77e00c112e721f4f49fc5e"
    },
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\browser-thread.json",
      "sha256": "38fab59f1c297426c45b42bce2a4c4a7c50cda0adebfe6d2d5ef2575421ae660"
    },
    {
      "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-browser-response.md",
      "sha256": "bdf6584451acaf3846b30826b7e14c825c213e18c3f715f8ca476d23b602f989"
    }
  ],
  "manifest_source": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\alpha-synuclein\\consensus-validation.json",
  "literature_cutoff_preserved": true,
  "independent_blinded_audit": false
}